Eleven Biotherapeutics (EBIO) Reports Q1 Loss of $0.25

Eleven Biotherapeutics (NASDAQ: EBIO) reported Q1 EPS of ($0.25), versus ($0.39) reported last year. Revenue for the quarter came in at $400 thousand, versus $200 thousand reported last year.

Cash Position: Cash and cash equivalents were $20.3 million as of March 31, 2017, compared to $25.3 million as of December 31, 2016.

For earnings history and earnings-related data on Eleven Biotherapeutics (EBIO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c